Evidence map›Paper›PMID 30920391›Full record

ArticleThe Journal of clinical investigation2019

Crossreactive public TCR sequences undergo positive selection in the human thymic repertoire.

Mohsen Khosravi-Maharlooei, Aleksandar Obradovic, Aditya Misra, Keshav Motwani, Markus Holzl, Howard R Seay, Susan DeWolf, Grace Nauman, Nichole Danzl, Haowei Li and 5 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Mohsen Khosravi-MaharlooeiColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Aleksandar ObradovicColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Aditya MisraColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Keshav MotwaniDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Markus HolzlColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Howard R SeayDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Susan DeWolfColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Grace NaumanColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Nichole DanzlColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Haowei LiColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Siu-Hong HoColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.
Robert WinchesterDivision of Rheumatology, Department of Medicine.
Yufeng ShenCenter for Computational Biology and Bioinformatics, and.
Todd M BruskoDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Megan SykesColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, Columbia University, New York, New York, USA.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
XENOGRAFT TOLERANCE THROUGH MIXED CHIMERISMP01AI045897 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Megan Sykes · 2000 to 2026
$71.9M
Translational Biomarker Analytical Core (TBAC)P30DK063608 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Anthony W Ferrante · 2003 to 2026
$36.7M
Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 1997 to 2026
$32.9M
MECHANISMS OF BETA CELL FAILURER01DK064819 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ACCILI, DOMENICO · 2003 to 2025
$10.5M
Human Islet Research Network (HIRN) Coordinating CenterU01DK104162 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NILAND, JOYCE CAROL · 2014 to 2018
$6.1M
The CD226 costimulatory axis in type 1 diabetesR01DK106191 · NIDDK · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 2016 to 2026
$4.4M
Modeling autoimmune pathogenesis and beta cell destruction by T1D immune systemsU01DK123559 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDERSON, MARK S, PARENT, AUDREY · 2019 to 2023
$4.3M
Mice with autologous human T1D-derived immune systems and iPSC-derived beta cellsUC4DK104207 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2014 to 2014
$3.8M
Genetic Regulation of Human Beta Cell DestructionUC4DK104194 · NIDDK · UNIVERSITY OF FLORIDA · PI MATHEWS, CLAYTON E · 2014 to 2014
$3.1M
Columbia University Graduate Training Program in Microbiology and ImmunologyT32AI106711 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Nicholas Arpaia, Uttiya Basu · 2014 to 2026
$2.1M
Immune Response to iPSC-Derived Beta Cells in Type 1 DiabetesR01DK103585 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2015 to 2018
$1.8M
NCI NIH HHS P30 CA013696NCRR NIH HHS S10 RR027050NIAID NIH HHS P01 AI042288NIAID NIH HHS P01 AI045897NIAID NIH HHS T32 AI106711NIDDK NIH HHS P30 DK063608NIDDK NIH HHS R01 DK064819NIDDK NIH HHS R01 DK103585NIDDK NIH HHS R01 DK106191NIDDK NIH HHS R01 DK106436NIDDK NIH HHS U01 DK104162NIDDK NIH HHS U01 DK123559NIDDK NIH HHS UC4 DK104194NIDDK NIH HHS UC4 DK104207NIH HHS S10 OD020056
6 · The paper itself

Abstract

We investigated human T-cell repertoire formation using high throughput TCRβ CDR3 sequencing in immunodeficient mice receiving human hematopoietic stem cells (HSCs) and human thymus grafts. Replicate humanized mice generated diverse and highly divergent repertoires. Repertoire narrowing and increased CDR3β sharing was observed during thymocyte selection. While hydrophobicity analysis implicated self-peptides in positive selection of the overall repertoire, positive selection favored shorter shared sequences that had reduced hydrophobicity at positions 6 and 7 of CDR3βs, suggesting weaker interactions with self-peptides than unshared sequences, possibly allowing escape from negative selection. Sharing was similar between autologous and allogeneic thymi and occurred between different cell subsets. Shared sequences were enriched for allo-crossreactive CDR3βs and for Type 1 diabetes-associated autoreactive CDR3βs. Single-cell TCR-sequencing showed increased sharing of CDR3αs compared to CDR3βs between mice. Our data collectively implicate preferential positive selection for shared human CDR3βs that are highly cross-reactive. While previous studies suggested a role for recombination bias in producing "public" sequences in mice, our study is the first to demonstrate a role for thymic selection. Our results implicate positive selection for promiscuous TCRβ sequences that likely evade negative selection, due to their low affinity for self-ligands, in the abundance of "public" human TCRβ sequences.

Indexed as

Complementarity Determining RegionsReceptors, Antigen, T-Cell, alpha-betaAnimalsCross ReactionsHumansMiceThymocytesThymus GlandComplementarity Determining RegionsReceptors, Antigen, T-Cell, alpha-betaAutoimmunityImmunologyT cell developmentT-cell receptorTolerance

Identifiers

PMID30920391
PMCPMC6546456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.